Switzerland· 63025001

Lemtrada

A alemtuzumab product containing alemtuzumabum, registered in Switzerland and dispensed under Swissmedic category A, on the national reimbursement list. The same ATC class is registered in 11 of our 19 countries.

Reimbursed in Switzerland (BAG SL)Cat A (Swissmedic)ATC L04AG06

Checked against BAG Spezialitätenliste (Switzerland) on

Informational only — not a medical device.

SOURCE REGISTER · CHBAG Spezialitätenliste (Switzerland)normalisedLemtradaATCL04AG06REGISTER NO.63025001PACKS LISTED1CHECKEDSeptember 12, 2026

Where it is registered

Alemtuzumab is registered in 11 of 19 countries.

Countries holding a registration under ATC L04AG06 (alemtuzumab), each read from that country’s own register.

  • This record: Switzerland, from BAG Spezialitätenliste (Switzerland)
  • 7 of them publish a price we can compare per daily dose

Alemtuzumab · ATC L04AG06

11 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Netherlands
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

BAG Spezialitätenliste (Switzerland)
Active substance
alemtuzumabum
Manufacturer
—
Country
Switzerland (CH)
ATC code
L04AG06
ATC class
Alemtuzumab
Defined daily dose
0.13 mg, P
Swissmedic category
A
Reimbursed
Yes
Source register
BAG Spezialitätenliste (Switzerland)
Last checked
September 12, 2026

Packs & prices · 1

1 priced
  • gtin
    7680630250018
    Durchstf
    CHF 7223.6

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

338 interactions on record for alemtuzumab.

Graded by severity as the source publishes them — 24 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Alemtuzumab · interactions on record

338 records

  • 24 severe
  • 314 moderate

Most severe, free to view

  • CladribineL01BB04severe
  • PrednisoloneA07EA01moderate
  • HydrocortisoneA07EA02moderate
  • PrednisoneA07EA03moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Alemtuzumab in 13 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All alemtuzumab products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Lemtrada
  • Liechtenstein · Lemtrada
  • Norway · Lemtrada

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of BAG Spezialitätenliste (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/345acebb-3c38-4215-8780-b206eec1da36
GET /v1/drugs/345acebb-3c38-4215-8780-b206eec1da36?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "unit": null,
  "strength": "alemtuzumabum 12 mg",
  "valid_from": "2025-01-01",
  "limitations": "[{\"description\":\"Bei erwachsenen Patienten mit hochaktiver schubförmig-remittierender Multipler Sklerose (RRMS), wenn zuvor eine vollständige und adäquate Behandlung mit mindestens zwei anderen krankheitsmodifizierenden Therapien (disease modifying treatments - DMTs) durchgeführt wurde oder bei Patienten mit hochaktiver RRMS, bei denen alle anderen DMTs kontraindiziert sind oder aus anderen Gründen nicht geeignet sind.<br>\\nLEMTRADA kann aufgrund des Sicherheitsprofils nur von erfahrenen Fachärzten der Neurologie FMH als Reservemittel in den neurologischen Kliniken der Weiterbildungskategorie A und B (mit Zugang zu Intensivmedizin) eingesetzt werden.<br>\\nEs können maximal 4 Behandlungszyklen LEMTRADA vergütet werden.<br>\\nDie Behandlung bedarf der Kostengutsprache durch den Krankenversicherer nach vorgängiger Konsultation des Vertrauensarztes.<br>\\n<br>\\n\",\"costApproval\":null,\"indication\":\"\",\"isNew\":false,\"limitationCode\":null,\"points\":null,\"priceModel\":null,\"title\":null,\"validFrom\":\"2025-01-01\",\"validTo\":\"2027-12-31\"}]",
  "galenic_form": "Inf Konz 12 mg/1.2ml",
  "therapeutic_area": null,
  "sl_inclusion_date": "2015-05-01",
  "self_retention_pct": 10
}

See everything about alemtuzumab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.